Back

AbbVie stock recovers after positive Phase 2 zumilokibart results

Verifying
  • AbbVie reported positive Phase 2 results for zumilokibart in atopic dermatitis.
  • 346 adults received low, mid or high doses, or placebo, during 16 weeks.
  • AbbVie plans Phase 3 development using the mid-dose regimen.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.